15 Sep 2021 07:00
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Share option awards
Manchester, UK - 15 September 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces an award of share options.
Award of options
The Company has today issued 1,160,000 options over Ordinary Shares of 0.1p under the Company's Enterprise Management Incentive (EMI) and unapproved share option schemes to a number of individuals in the UK and international subsidiaries.
The options are exercisable in three tranches over three financial years and are subject to certain performance conditions. The options awarded are exercisable up to 14 September 2031, at a price of 15 pence per share representing an approximation of the 30 day average share price.
Following the award of these new options, and taking into account lapsed options, the Company has 59,459,172 shares under its market-based and performance-based option schemes.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 investors@yourgene-health.com | |||
Barry Hextall, Chief Financial Officer | ||||
Joanne Cross, Director of Marketing | ||||
Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 | |||
Liam Murray / James Caithie / Ludovico Lazzaretti |
| |||
Singer Capital Markets (Joint Corporate Broker) | Tel: +44 (0)20 7496 3000 | |||
Aubrey Powell / Tom Salvesen / George Tzimas | ||||
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | Tel: +44 (0)20 7710 7600 | |||
Nicholas Moore / Matthew Blawat / Ben Maddison | ||||
Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com | |||
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / Mob: 07584 391 303 | |||
| ||||
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genomic services and technologies. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. The Group's flagship in vitro diagnostic products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping.
Yourgene has a range of innovative DNA sample preparation platforms, powered by Ranger® Technology, the Yourgene LightBench® and Yourgene QS250, ideal for cell-free DNA applications in NIPT and oncology including liquid biopsy.
Yourgene Genomic Services is a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
Yourgene Health is headquartered in Manchester, UK with facilities in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". Follow us on LinkedIn and Twitter. Further information is available at www.yourgene-health.com
YGEN.L (YGEN)